Bicara Therapeutics (BCAX) grants 100,000 stock options to its CMO

Rhea-AI Filing Summary

Bicara Therapeutics Inc. reported a new stock option grant to its Chief Medical Officer, David Raben. On February 2, 2026, he received a stock option covering 100,000 shares of common stock at an exercise price of $16.76 per share, expiring on February 2, 2036.

The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, and each installment requires his continued service on the vesting date. Following this grant, he beneficially owns 100,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Raben David

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	100,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 100,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raben David

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.76	02/02/2026		A		100,000		(1)	02/02/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

	/s/ Lara Meisner, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Bicara Therapeutics (BCAX) report in this Form 4 filing?

Bicara Therapeutics reported a stock option grant to Chief Medical Officer David Raben. He received options for 100,000 shares of common stock on February 2, 2026, under a vesting schedule tied to his continued service with the company.

How many Bicara Therapeutics (BCAX) shares are covered by the new stock option?

The new stock option covers 100,000 shares of Bicara Therapeutics common stock. These options were granted as a derivative security and are held directly by David Raben, the company’s Chief Medical Officer, according to the Form 4 insider transaction data.

What is the exercise price and expiration date of David Raben’s Bicara options?

The stock option has an exercise price of $16.76 per share and expires on February 2, 2036. This means Raben can choose to buy up to 100,000 shares at $16.76 before the stated expiration date, subject to vesting conditions.

How do the Bicara Therapeutics (BCAX) options granted to David Raben vest?

The options vest in sixteen equal quarterly installments following February 2, 2026. Each installment vests only if David Raben continues serving the company on the applicable vesting date, aligning his long-term incentives with ongoing service at Bicara Therapeutics.

What is David Raben’s beneficial ownership after this Bicara Therapeutics option grant?

After the transaction, David Raben beneficially owns 100,000 derivative securities in the form of stock options. The Form 4 indicates this ownership is direct, reflecting the full 100,000 options granted on February 2, 2026, subject to the specified vesting schedule.